Research Paper Volume 13, Issue 15 pp 19415—19441
Development and validation of an intra-tumor heterogeneity-related signature to predict prognosis of bladder cancer: a study based on single-cell RNA-seq
Figure 9. The candidate compounds targeting HRS. (A) The volcano plot displayed the DEGs between low-HRS and high-HRS cases. (B–I) Seven compounds, including cephaeline (C), LY-294002 (D), lycorine (E), naltrexone (F), nefopam (G), tanespimycin (H), and wortmannin (I), were identified.